BRPI9715334B8 - agentes estrogênicos e composição farmacêutica compreendendo os mesmos. - Google Patents

agentes estrogênicos e composição farmacêutica compreendendo os mesmos.

Info

Publication number
BRPI9715334B8
BRPI9715334B8 BRPI9715334A BR9715334A BRPI9715334B8 BR PI9715334 B8 BRPI9715334 B8 BR PI9715334B8 BR PI9715334 A BRPI9715334 A BR PI9715334A BR 9715334 A BR9715334 A BR 9715334A BR PI9715334 B8 BRPI9715334 B8 BR PI9715334B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
estrogenic agents
estrogenic
compounds
agents
Prior art date
Application number
BRPI9715334A
Other languages
English (en)
Portuguese (pt)
Other versions
BR9715334B1 (pt
Inventor
Attilio Santilli Arthur
Dinh Tran Bach
Paul Miller Chris
David Collini Michael
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27092026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9715334(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/833,271 external-priority patent/US5998402A/en
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR9715334B1 publication Critical patent/BR9715334B1/pt
Publication of BRPI9715334B8 publication Critical patent/BRPI9715334B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI9715334A 1996-04-19 1997-04-22 agentes estrogênicos e composição farmacêutica compreendendo os mesmos. BRPI9715334B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63397496A 1996-04-19 1996-04-19
US08/833,271 US5998402A (en) 1996-04-19 1997-04-04 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents

Publications (2)

Publication Number Publication Date
BR9715334B1 BR9715334B1 (pt) 2012-09-04
BRPI9715334B8 true BRPI9715334B8 (pt) 2021-05-25

Family

ID=27092026

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9715334A BRPI9715334B8 (pt) 1996-04-19 1997-04-22 agentes estrogênicos e composição farmacêutica compreendendo os mesmos.

Country Status (26)

Country Link
EP (1) EP0802183B1 (OSRAM)
JP (1) JP4093611B2 (OSRAM)
KR (1) KR100480193B1 (OSRAM)
CN (1) CN1106383C (OSRAM)
AR (1) AR011503A1 (OSRAM)
AT (1) ATE206701T1 (OSRAM)
AU (1) AU710149B2 (OSRAM)
BR (1) BRPI9715334B8 (OSRAM)
CO (1) CO4900051A1 (OSRAM)
CY (2) CY2325B1 (OSRAM)
CZ (1) CZ291701B6 (OSRAM)
DE (2) DE69707189T2 (OSRAM)
DK (1) DK0802183T3 (OSRAM)
EA (1) EA001448B1 (OSRAM)
ES (1) ES2162198T3 (OSRAM)
FR (1) FR09C0048I2 (OSRAM)
HU (1) HU227077B1 (OSRAM)
IL (1) IL120701A (OSRAM)
LU (1) LU91608I2 (OSRAM)
MX (1) MX9702865A (OSRAM)
NL (1) NL300416I2 (OSRAM)
NO (2) NO309564B1 (OSRAM)
NZ (1) NZ314601A (OSRAM)
PT (1) PT802183E (OSRAM)
SK (1) SK281737B6 (OSRAM)
UA (1) UA48148C2 (OSRAM)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048797A1 (en) * 1997-04-30 1998-11-05 Eli Lilly And Company Antithrombotic agents
CA2287984A1 (en) 1997-05-01 1998-11-05 Gerald Floyd Smith Antithrombotic agents
UA68365C2 (en) * 1997-11-06 2004-08-16 Wyeth Corp Peroral contraception by combination of anti-estrogen and progestin
US6069153A (en) * 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
CN1173973C (zh) * 1998-05-12 2004-11-03 惠氏公司 苯并咔唑和茚并吲哚衍生的雌激素药
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
OA11552A (en) * 1998-05-15 2004-06-07 American Home Prod 2-Phenyl-1-Ä4-(2-Aminoethoxy)-BenzylÜ-Indole in Combination with Estrogens.
AU3894299A (en) * 1998-05-15 1999-12-06 American Home Products Corporation Compositions comprising 2-phenyl-indole compounds and estrogen formulations
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
ATE258934T1 (de) 1998-10-30 2004-02-15 Lilly Co Eli Azaindol derivate und ihre verwendung als antithrombotische wirkstoffe
US6380185B1 (en) 1999-03-04 2002-04-30 American Home Products Corporation N-substituted benzoyl indoles as estrogenic agents
EP1159268A1 (en) * 1999-03-04 2001-12-05 American Home Products Corporation N-SUBSTITUTED BENzOYL INDOLES AS ESTROGENIC AGENTS
TWI220898B (en) * 1999-03-04 2004-09-11 Wyeth Corp N-substituted indolines as estrogenic agents
US6358943B1 (en) 1999-03-04 2002-03-19 American Home Products Corporation N-substituted indolines as estrogenic agents
WO2001019839A1 (en) * 1999-09-13 2001-03-22 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1h-indol-5-ols
US6380166B1 (en) 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
NZ534348A (en) * 2000-01-28 2006-06-30 Endorech Inc Selective estrogen receptor modulators in combination with estrogens
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US6358991B2 (en) * 2000-07-06 2002-03-19 American Home Products Corporation Methods of treating neuropeptide Y-related conditions
AU2001271706A1 (en) * 2000-07-06 2002-01-21 American Home Products Corporation Use of substituted indole compounds for treating breast disorders
HK1052877A1 (zh) * 2000-07-06 2003-10-03 Wyeth Ssri与雌激素剂之组合
WO2002003989A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating sphincter incontinence
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
AU2001271784A1 (en) * 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
US6509332B2 (en) 2000-07-06 2003-01-21 Wyeth Methods of treating excessive intraocular pressure
AR030064A1 (es) * 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
EP1656938A1 (en) 2000-07-06 2006-05-17 Wyeth Combinations of SSRI and estrogenic agents
CA2414111A1 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for increasing nitric oxide synthase activity
EP1177787A3 (en) * 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
CA2444787A1 (en) 2001-05-22 2002-11-28 Eli Lilly And Company Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
WO2002094788A1 (en) 2001-05-22 2002-11-28 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
WO2003105834A1 (en) * 2002-06-13 2003-12-24 Wyeth Bazedoxifene treatment regimens
EP1530470B9 (en) 2002-07-22 2010-04-07 Eli Lilly And Company Selective estrogen receptor modulators containing a phenylsulfonyl group
AU2003292625B2 (en) 2002-12-26 2008-07-24 Eisai R & D Management Co., Ltd. Selective estrogen receptor modulators
US7250440B2 (en) * 2003-08-12 2007-07-31 Wyeth (Hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivatives as estrogenic agents
AU2005233133A1 (en) 2004-04-07 2005-10-27 Wyeth Crystalline polymorph of a bazedoxifene acetate
RU2006132352A (ru) 2004-04-07 2008-05-20 Вайет (Us) Кристаллическая полиморфная форма базедоксифен ацетата
KR20060134146A (ko) 2004-04-08 2006-12-27 와이어쓰 선택적 에스트로겐 수용체 모듈레이터로서의 바제독시펜아스코르베이트
CA2573185A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7645881B2 (en) 2004-07-22 2010-01-12 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US20060030591A1 (en) * 2004-08-05 2006-02-09 Wyeth Crystalline polymorph of pipindoxifene hydrochloride monohydrate
CN102406650A (zh) 2004-10-20 2012-04-11 恩多研究公司 单独的性甾体前体或与选择性雌激素受体调节剂联合用于防治绝经后女性的阴道疾病和病症
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
US20100087661A1 (en) * 2007-02-12 2010-04-08 Josef Jirman Method for the preparation of 5-benzyloxy-2-(4-benzyloxphenyl)-3-methyl-1h-indole
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
CA2714494A1 (en) * 2008-02-11 2009-08-20 Wyeth Llc Methods of preparing polymorphic form a of bazedoxifene acetate
KR20160067981A (ko) 2008-04-16 2016-06-14 카로 바이오 아베 신규한 에스트로겐 수용체 리간드
CN102395561A (zh) * 2009-04-13 2012-03-28 桑多斯股份公司 合成巴多昔芬乙酸酯及其中间体的方法
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
ITMI20091109A1 (it) * 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
KR20140089402A (ko) 2010-06-16 2014-07-14 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
US7968732B1 (en) 2010-09-07 2011-06-28 Divi's Laboratories, Ltd. Process for the preparation of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole
WO2012037187A2 (en) 2010-09-14 2012-03-22 Dr. Reddy's Laboratories Ltd. Preparation of crystalline bazedoxifene and its salts
US8569483B2 (en) 2011-06-21 2013-10-29 Divi's Laboratories, Ltd. Process for the preparation of bazedoxifene acetate and intermediates thereof
CN102690225B (zh) * 2012-04-11 2014-12-24 南京友杰医药科技有限公司 巴多昔芬的合成方法
JP2016518449A (ja) * 2013-05-15 2016-06-23 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インドール製剤を調製するためのプロセスおよび中間体
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
PL3122426T3 (pl) 2014-03-28 2023-05-15 Duke University Leczenie raka sutka z zastosowaniem selektywnych modulatorów receptora estrogenowego
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
EP3233828B1 (en) * 2014-12-18 2020-03-04 F. Hoffmann-La Roche AG Estrogen receptor modulators and uses thereof
KR20190110400A (ko) 2018-03-20 2019-09-30 엠에프씨 주식회사 새로운 중간체를 이용한 바제독시펜의 제조방법
IT201800006562A1 (it) * 2018-06-21 2019-12-21 Procedimento e intermedi utili per la preparazione di indoli
IT201900001923A1 (it) 2019-02-11 2020-08-11 Erregierre Spa Sali di bazedoxifene utili per la preparazione di bazedoxifene acetato
US11246874B1 (en) 2021-04-20 2022-02-15 Oxygen Biotech LLC Treatment of COVID-19

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU373941A3 (OSRAM) * 1970-01-21 1973-03-12
DE2557342A1 (de) * 1975-12-19 1977-06-30 Hoechst Ag Basisch substituierte indolderivate und verfahren zu ihrer herstellung
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
DE3232968A1 (de) * 1981-09-10 1983-06-09 Degussa Ag, 6000 Frankfurt Neue 2-(hydroxy-phenyl)-indole und verfahren zu deren herstellung
CA1241660A (en) * 1984-06-25 1988-09-06 Yvan Guindon Indole-2-alkanoic acids
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
DE3821148A1 (de) * 1988-06-23 1989-12-28 Erwin Von Dr Angerer Aminoalkylindole, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
GB9004301D0 (en) * 1990-02-26 1990-04-18 Fujisawa Pharmaceutical Co Indolebutyric acid derivatives and process for preparation thereof
US5051442A (en) * 1990-04-25 1991-09-24 Merrell Dow Pharmaceuticals Inc. 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof
AU665690B2 (en) * 1992-05-08 1996-01-11 Otsuka Pharmaceutical Factory, Inc. Indole derivative
EP0634169B1 (en) * 1993-06-29 2000-01-05 Takeda Chemical Industries, Ltd. Quinoline or quinazoline derivatives and their use in the manufacture of a medicament for the treatment of osteoporosis
GB9326332D0 (en) * 1993-12-23 1994-02-23 Karo Bio Indole derivatives
DE4426625A1 (de) * 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln

Also Published As

Publication number Publication date
KR100480193B1 (ko) 2005-08-30
EA199700044A1 (ru) 1997-12-30
HUP9700777A3 (en) 2000-04-28
NO2009025I2 (no) 2010-11-22
CO4900051A1 (es) 2000-03-27
AR011503A1 (es) 2000-08-30
HUP9700777A2 (hu) 1999-06-28
IL120701A0 (en) 1997-09-30
FR09C0048I1 (OSRAM) 2009-06-11
EP0802183A1 (en) 1997-10-22
DE69707189T2 (de) 2002-06-20
LU91608I2 (fr) 2009-11-23
AU1892097A (en) 1997-10-23
JPH1036346A (ja) 1998-02-10
NL300416I1 (nl) 2009-12-01
CY2009016I1 (el) 2010-07-28
CZ117597A3 (en) 1997-11-12
DE69707189D1 (de) 2001-11-15
CY2009016I2 (el) 2010-07-28
KR970069037A (ko) 1997-11-07
NO309564B1 (no) 2001-02-19
FR09C0048I2 (OSRAM) 2010-06-11
DK0802183T3 (da) 2002-02-04
NL300416I2 (nl) 2010-02-01
HU227077B1 (en) 2010-06-28
NO971815D0 (no) 1997-04-18
SK47297A3 (en) 1997-11-05
SK281737B6 (sk) 2001-07-10
ATE206701T1 (de) 2001-10-15
ES2162198T3 (es) 2001-12-16
CY2325B1 (en) 2003-11-14
CN1170719A (zh) 1998-01-21
CN1106383C (zh) 2003-04-23
HU9700777D0 (en) 1997-06-30
MX9702865A (es) 1998-05-31
BR9715334B1 (pt) 2012-09-04
NO2009025I1 (no) 2009-11-30
AU710149B2 (en) 1999-09-16
HK1002863A1 (en) 1998-09-25
PT802183E (pt) 2002-03-28
IL120701A (en) 2005-09-25
EA001448B1 (ru) 2001-04-23
NO971815L (no) 1997-10-20
UA48148C2 (uk) 2002-08-15
JP4093611B2 (ja) 2008-06-04
EP0802183B1 (en) 2001-10-10
DE122009000061I1 (de) 2009-12-31
CZ291701B6 (cs) 2003-05-14
NZ314601A (en) 1999-09-29

Similar Documents

Publication Publication Date Title
BRPI9715334B8 (pt) agentes estrogênicos e composição farmacêutica compreendendo os mesmos.
TR200000481T2 (tr) N-Alkonoilfenilalenin türevleri.
AR011116A1 (es) Compuesto derivado de n-hidroxi-beta-sulfonil propionamida y composicion farmaceutica que lo contiene
BR9714064A (pt) Composição farmacêutica
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
TR199901305T2 (xx) Calpain-�nleyicileri olarak ketonbenzamidler
HN2000000109A (es) Trifluorbutenos nematicidas
PT98710A (pt) Processo de preparacao de compostos de indolilo substituidos e de composicoes farmaceuticas que os contem
EA200000920A1 (ru) Производные бициклических гидроксамовых кислот
BR9811099A (pt) Inibidores de urocinase
AP1424A (en) 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens.
MA24643A1 (fr) Tetrahydro-naphtalenes substitues et composes analogues
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
MX9804588A (es) Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel.
ATE423562T1 (de) Alpha-ketoamidhaltige multikatalytische protease inhibitoren
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
KR950031060A (ko) 골다공증 치료용 약제학적 조성물
NZ192195A (en) 1-triazolyl-2-hydroxy-2-phenyl-3-aryl-propanes and pharmaceutical compositions
BR9707247A (pt) Diidrobenzofurano e compostos relacionados úteis como agentes antiinflamatórios
ES2156642T3 (es) Composicion que comprende un derivado de acido cinamico y un polimero poliaminado.
MA19882A1 (fr) Derives d'acides w-amines, leur preparation et utilisation ainsi que les compositions contenant ces acides.
SE9801494D0 (sv) Novel use
NO954145D0 (no) Nasale aromatiske frigjörende preparater
DE69814109D1 (de) 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analoga
BR9915955A (pt) Composição cosmética para cuidado com a pele, processo cosmético para tratar uma pele envelhecida e uso de 4- cromanona

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/09/2012, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061589/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132279-24.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: WARSAW ORTHOPEDIC, WISTA LABORATORIES, WYETH, WYETH HOLDINGS CORPORATION.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/04/1997 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 22/04/2017